Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
- Saturday, October 24, 2026, 2:11
- Business
- Add a comment
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP…
About the Author
adminasapcorp has written 42434 stories on this site.